Details of the Drug
General Information of Drug (ID: DMCDZ8A)
| Drug Name |
(S)-2-amino-2-p-tolylacetic acid
|
||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms |
119615-71-3; CHEMBL378582; (S)-2-Amino-2-(p-tolyl)acetic acid; (2S)-2-amino-2-(4-methylphenyl)acetic acid; (S)-2-amino-2-p-tolylacetic acid; AC1ODTRS; 4-Methyl-L-phenylglycine; (S)-Amino-p-tolyl-acetic acid; SCHEMBL11728987; DTXSID20427275; ZINC2567159; BENZENEACETIC ACID, ALPHA-AMINO-4-METHYL-, (ALPHAS)- (9CI); BDBM50179719; AKOS006275863; (2S)-Amino(4-methylphenyl)acetic acid; AJ-41354; KB-276738; AB1006787; Benzeneacetic acid, a-amino-4-methyl-, (aS)-
|
||||||||||||||||||||||
| Indication |
|
||||||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||||||
| #Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 165.19 | |||||||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | -1.3 | ||||||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 3 | ||||||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Discovery agent | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | N.A. | |||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||


